Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results [Yahoo! Finance]
Theriva Biologics, Inc. (TOVX)
Company Research
Source: Yahoo! Finance
the VIRAGE Phase 2b trial presented at the European Society for Medical Oncology (ESMO) Annual Congress 2025 - - Next generation oncolytic virus VCN-12 preclinical data presented at the 32 nd Annual Congress European Society of Gene & Cell Therapy (ESGCT) - - Cash and cash equivalents of $7.5 millon as of September 30, 2025; recent capital raises increase cash to $15.5 million as of November 10, 2025 and extends cash runway into Q1 2027 - ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. “Recent presentations of clinical data for VCN-01 and preclinical data for VCN-12 at medical congresses have highlighted the progress made across our oncology pipeline,” said Steven A. Shallcross, Chief Exe
Show less
Read more
Impact Snapshot
Event Time:
TOVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TOVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TOVX alerts
High impacting Theriva Biologics, Inc. news events
Weekly update
A roundup of the hottest topics
TOVX
News
- Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial ResultsGlobeNewswire
- Theriva Biologics Provides Response to Unusual Market ActionGlobeNewswire
- Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross ProceedsGlobeNewswire
- Theriva™ Biologics Announces Upcoming Presentations at Medical MeetingsGlobeNewswire
- Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)GlobeNewswire
TOVX
Sec Filings
- 12/3/25 - Form 424B5
- 12/3/25 - Form EFFECT
- 11/12/25 - Form DEFA14A
- TOVX's page on the SEC website